Mixed dementia: A review of the evidence.

Dement Neuropsychol

Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia. Instituto Peruano de Neurociencias. Lima, Perú.

Published: January 2017

Mixed dementia is the coexistence of Alzheimer's disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therapy of Mixed Vascular-Alzheimer Dementia (MVAD). The literature was reviewed for articles published between 1990-2016 by using the keywords linked to MVAD. Neuropathological studies indicate that MVAD is a very common pathological finding in the elderly with a prevalence about of 22%. The distinction between Alzheimer's dementia and vascular dementia (VD) is complex because their clinical presentation can overlap. There are international criteria for the MVAD diagnosis. The pharmacologic therapy shows modest clinical benefits that are similar among all drugs used in patients with Alzheimer's dementia and VD. The non-pharmacologic therapy includes the rigorous management of cardiovascular risk factors (especially hypertension) and the promotion of a healthy diet. The diagnosis and treatment of MVAD cannot be improved without further studies. Currently available medications provide only modest clinical benefits once a patient has developed MVAD. In subjects at risk, the antihypertensive therapy and healthy diet should be recommend for preventing or slowing the progression of MVAD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769994PMC
http://dx.doi.org/10.1590/1980-57642016dn11-040005DOI Listing

Publication Analysis

Top Keywords

mixed dementia
8
diagnosis treatment
8
alzheimer's dementia
8
modest clinical
8
clinical benefits
8
healthy diet
8
mvad
7
dementia
5
dementia review
4
review evidence
4

Similar Publications

Introduction: Informal care estimates for use in health-economic models are lacking. We aimed to estimate the association between informal care time and dementia symptoms across Europe.

Methods: A secondary analysis was performed on 13,529 observations in 5,369 persons from 9 European pooled cohort or trial studies in community-dwelling persons with dementia.

View Article and Find Full Text PDF

Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).

Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.

Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.

View Article and Find Full Text PDF

Objectives: There are limited mental health support services in Australia that address the well-being of family members of aged care residents. The aim of this project was to evaluate the feasibility, acceptability and preliminary effectiveness of an online program designed to support residents' families.

Methods: This one-arm mixed methods project examined uptake, attendance and retention patterns, satisfaction and experience with the service, and pre- and postoutcomes with respect to depressive and anxiety symptoms and loneliness.

View Article and Find Full Text PDF

Loss of Insight in Syndromes Associated with Frontotemporal Lobar Degeneration: Clinical and Imaging Features.

Am J Geriatr Psychiatry

December 2024

Department of Clinical and Experimental Sciences (DA, BB), University of Brescia, Brescia, Italy; Molecular Markers Laboratory (BB), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. Electronic address:

Objectives: The present study aims to assess the prevalence, associated clinical symptoms, longitudinal changes, and imaging correlates of Loss of Insight (LOI), which is still unexplored in syndromes associated with Frontotemporal Lobar Degeneration (FTLD).

Design: Retrospective longitudinal cohort study, from Oct 2009 to Feb 2023.

Setting: Tertiary Frontotemporal Dementia research clinic.

View Article and Find Full Text PDF

Two Decades of the Walking While Talking Test: A Narrative Review.

J Am Med Dir Assoc

January 2025

Department of Neurology, Renaissance School of Medicine, Stony Brook, NY, United States.

Objectives: Early research reported that older adults who stopped walking when they began a conversation were more likely to fall in the future. As a systematic measure of dual-task performance, Verghese and colleagues developed the Walking While Talking (WWT) test, in which a person walks at a normal pace while reciting alternate letters of the alphabet. The present paper highlights key findings from the 2 decades of research using the WWT test.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!